Sea Creation Pharmaceuticals (688302.SH) has completed the first subject's enrollment in China's clinical trial of its self-developed drug HP515.

19/01/2025

GMT Eight

Haisco Pharmaceutical (688302.SH) announced that the clinical trial of the company's independently developed HP515 tablets for the treatment of non-alcoholic steatohepatitis (NASH) recently completed the first subject enrollment.

Shanxi Xinghuacun Fen Wine Factory (600809.SH) plans to distribute a dividend of 2.46 yuan per share on January 24th.

Shanghai International Port (600018.SH) reported a net profit of 14.6 billion yuan in 2024, a year-on-year increase of 10.6%.

Contact: contact@gmteight.com

Sea Creation Pharmaceuticals (688302.SH) has completed the first subject's enrollment in China's clinical trial of its self-developed drug HP515.

RECOMMEND

Guotai Junan: Highway Industry High Dividend Cash Flow Stable Policy Optimization May Accelerate

China Securities Co., Ltd.: Continue to actively deploy, corrections are opportunities.

Technical analysis indicates that the stock price is on the verge of rebounding, how can REMEGEN (09995) achieve long-term valuation regression after profit warning?